When was Vaxart founded?

Vaxart was founded in 2004 and raised its 1st funding round 3 years after it was founded.

Where is Vaxart located?

Vaxart is headquartered in San Francisco, United States.

How many employees does Vaxart have?

As of Sep 30, 2026, the latest employee count at Vaxart is 110.

Is Vaxart a funded company?

Vaxart is a funded company, having raised a total of $58M across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 01, 2007.

When was the latest funding round of Vaxart?

Vaxart's latest funding was a $***** Series C round on Jan 08, 2015, with participation from 1 investor.

What is the annual revenue of Vaxart?

Annual revenue of Vaxart is between $100M and $500M as on Dec 31, 2025

Where does Vaxart rank among its competitors?

Vaxart ranks 3rd amongst 363 active competitors, of which 93 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Leyden Labs, which secured $45.5M in Jun, 2026.

Who are the top competitors of Vaxart?

Vaxart's top competitors include HOOKIPA Pharma, Atea and Brii Biosciences. Among them, Leyden Labs secured the most recent funding round in June, 2026.

Vaxart - 2026 Company Profile, Funding, Competitors & Financials

Vaxart is a public company based in San Francisco (United States), founded in 2004. It operates as a Developer of therapeutic solutions for treating multiple infectious diseases. Vaxart has raised $58M in funding from investors like Life Science Angels, Quantum Technology Partners and Care Capital. The company has 363 active competitors, including 93 funded and 91 that have exited. Its top competitors include companies like HOOKIPA Pharma, Atea and Brii Biosciences.

Company Details

Developer of therapeutic solutions for treating multiple infectious diseases. The proprietary delivery platform of the company can deliver recombinant vaccines, thus enabling vaxart to introduce oral versions of certain vaccines. The pipeline includes vaccines for seasonal influenza, norovirus, RSV, HSV-2, avian influenza vaccine, and ebola vaccine. It has also developed vaccines for the treatment of influenza.

Key Metrics

Founded Year

2004

Location

San Francisco, United States

Stage

Public

Total Funding

$58M in 8 rounds

Latest Funding Round

Series C, Jan 08, 2015, $*****

Investors

Life Science Angels & 9 more

Ranked

3^rd among 363 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

110 as on Sep 30, 2026

Similar Companies

HOOKIPA Pharma & 445 more

Exit Details

Public

View Vaxart's full profile

Vaxart is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Vaxart, Inc. CIN: 72444 , United States, Active		$100M - $500M (As on Dec 31, 2025)	115 (As on Dec 31, 2021)	-
VAXART, INC. CIN: 59-1212264 , United States, Active		-	110 (As on Dec 31, 2021)	-

Vaxart got listed on Feb 12, 2018.

Click here to take a look at Vaxart's IPO in detail

Vaxart has raised a total funding of $58M over 8 rounds. Its first funding round was on Apr 01, 2007. Its latest funding round was a Series C round on Jan 08, 2015 for $*****. 1 investor participated in its latest round. Vaxart has 10 institutional investors.

Here is the list of recent funding rounds of Vaxart:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 08, 2015	9622049	Series C	8517640	7442984	7552760	4883512
Aug 05, 2013	5212285	Series C	9570698	2875831	9286016	2624742
Jun 29, 2012	2493839	Series B	4194250	2370624	Care Capital & 2 more	8382951

Access funding benchmarks and valuations. Sign up today!

View details of Vaxart's funding rounds and investors

Vaxart's employee count trend

Vaxart has 110 employees as of Sep 26. Here is Vaxart's employee count trend over the years:

Uncover Vaxart's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vaxart include HOOKIPA Pharma, Atea and Brii Biosciences. Here is the list of Top 10 competitors of Vaxart, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	Sofinnova Partners, Forbion & 12 others	69/100
2nd	Atea 2014, Boston (United States), Public	Developer of therapeutics for viral diseases	$293M	Bain Capital Life Sciences, GSA Capital Partners ... & 18 others	67/100
3rd	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Care Capital, Codon Capital & 8 others	64/100
4th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	HongShan, Invesco & 7 others	63/100
5th	Leyden Labs 2020, Leiden (Netherlands), Series B	Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa	$303M	Google Ventures, Clavystbio & 14 others	63/100
6th	eradivir 2020, West Lafayette (United States), Series A	Developer of immunotherapies for the treatment of infectious diseases	$20.4M	Research Bridge Partners, America’s Seed Fund ... & 3 others	62/100
7th	Memo Therapeutics 2012, Schlieren (Switzerland), Acquired	Developer of antibodies for treating infectious diseases and cancer	$97.2M	Swisscanto, Verve Ventures & 17 others	61/100
8th	VBI Vaccines 2001, Cambridge (United States), Public	Developer of vaccines for the treatment of infectious diseases	$65.1M	RTW Investments, Perceptive Advisors & 7 others	60/100
9th	Ascletis 2011, Hangzhou (China), Series B	Developer of small molecules for the treatment of multiple diseases	$255M	CBC Group, Goldman Sachs & 5 others	60/100
10th	Ocugen 2013, Aurora (United States), Public	Developer of therapeutic solutions to treat various eye disorders	-	Checkmate Capital, Colorado Office of Economic Development and International Trade ... & 5 others	59/100